Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome (Q80033733)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17384358%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17384358%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17384358%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Jimmy Jose

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17384358%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Barkur Anathakrishna Shastry

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17384358%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17384358%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Health-System Pharmacy

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17384358%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17384358%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17384358%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

726-729

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17384358%20AND%20SRC:MED&resulttype=core&format=json

Rhabdomyolysis and HMG-CoA reductase inhibitors

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

FDA adverse event reports on statin-associated rhabdomyolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Clinical perspectives of statin-induced rhabdomyolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Inhibition of Cholesterol Synthesis by Squalene Synthase Inhibitors Does Not Induce Myotoxicityin Vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Lovastatin decreases coenzyme Q levels in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Experimental evaluation of the effects of pravastatin on electrophysiological parameters of rat skeletal muscle

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Statin-associated myopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Rhabdomyolysis induced by a single dose of a statin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Statin-associated rhabdomyolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

A method for estimating the probability of adverse drug reactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Patients with chronic glucocorticoid treatment develop changes in muscle glycogen metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

Steroid myopathy in connective tissue disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060241

31 March 2020

Identifiers

DOI

10.2146/AJHP060241

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17384358%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference